<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478256</url>
  </required_header>
  <id_info>
    <org_study_id>SAIRB-11-0007</org_study_id>
    <nct_id>NCT01478256</nct_id>
  </id_info>
  <brief_title>Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis</brief_title>
  <official_title>A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John, George, M.D.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>John, George, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at the improvements in signs and symptoms in patients with inflammation of
      the lids, blepharitis, using two different FDA approved topical antibiotic agents,
      Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients for
      microbiologic evidence of improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot project involving thirty patients with a specific form of inflammtion of the
      lids called anterior blepharitis. The patients are graded for their signs a symptoms and then
      randomized to receive either topical Besifloxocin or Erythromycin in addition to standard lid
      hygiene measures. All patients have cultures of their eyelids performed prior to initiating
      therapy and are followed for four weeks. The antibiotics are used for two weeks following
      which repeat cultures of the lids are obtained. The patients are followed for one additional
      week to ensure that there is no recurrence of their symptoms once the antibiotics are
      discontinued.

      Only adult patients (age 18-100)and women who are not of child bearing potential are included
      in this study. Then patients have to have symptoms and signs of the disease, blepharitis.
      Patient who are on unstable antibiotic or steroid regimens and those who cannot discontinue
      contact lens use are not included in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Signs and Symptoms of Blepharitis</measure>
    <time_frame>Four weeks</time_frame>
    <description>Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics</measure>
    <time_frame>Three weeks</time_frame>
    <description>Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Besifloxocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of topical besifloxocin to treat acute blepharitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Erythromycin ointment for treatment of acute blepharitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>Topical erythromycin ointment twice a day</description>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxocin</intervention_name>
    <description>Topical Besifloxocin twice a day</description>
    <arm_group_label>Besifloxocin</arm_group_label>
    <other_name>Besivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Acute blepharitis, age 18-100, Signs and symptoms of blepharitis -

        Exclusion Criteria: women of child bearing potential, eye surgery within three months of
        study, contact lens wear, use of topical or antibacterial agents in past two weeks, use of
        topical or oral steroids in past two weeks unless stable dosage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>George John, M.D.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <results_first_submitted>April 9, 2013</results_first_submitted>
  <results_first_submitted_qc>September 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2013</results_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John, George, M.D.</investigator_affiliation>
    <investigator_full_name>George John, M.D.</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>blepharitis</keyword>
  <keyword>topical erythromycin</keyword>
  <keyword>topical besifloxocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Besifloxocin</title>
          <description>Use of topical besifloxocin twice a day to treat acute blepharitis</description>
        </group>
        <group group_id="P2">
          <title>Erythromycin</title>
          <description>Topical Erythromycin ointment twice a day for treatment of acute blepharitis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Besifloxocin</title>
          <description>Use of topical besifloxocin twice a day to treat acute blepharitis</description>
        </group>
        <group group_id="B2">
          <title>Erythromycin</title>
          <description>Topical Erythromycin ointment twice a day for treatment of acute blepharitis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="10"/>
                    <measurement group_id="B2" value="50" spread="12"/>
                    <measurement group_id="B3" value="49" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Signs and Symptoms of Blepharitis</title>
        <description>Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics</description>
        <time_frame>Four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Besifloxocin</title>
            <description>Use of topical besifloxocin to treat acute blepharitis</description>
          </group>
          <group group_id="O2">
            <title>Erythromycin</title>
            <description>Topical Erythromycin ointment for treatment of acute blepharitis</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Signs and Symptoms of Blepharitis</title>
          <description>Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics</title>
        <description>Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis</description>
        <time_frame>Three weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Besifloxocin</title>
            <description>Use of topical besifloxocin twice a day to treat acute blepharitis</description>
          </group>
          <group group_id="O2">
            <title>Erythromycin</title>
            <description>Topical Erythromycin ointment twice a day for treatment of acute blepharitis</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics</title>
          <description>Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Besifloxocin</title>
          <description>Use of topical besifloxocin to treat acute blepharitis</description>
        </group>
        <group group_id="E2">
          <title>Erythromycin</title>
          <description>Topical Erythromycin ointment for treatment of acute blepharitis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George John</name_or_title>
      <organization>George John MD</organization>
      <phone>5028949757</phone>
      <email>grjohn777@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

